Lonza has concluded the divestment of its Peptides Business located in Braine-l’Alleud, Belgium, to PolyPeptide. The facility, with approximately 280 employees, was the centre for peptide chemical development and manufacturing within Lonza. The intention to divest was announced at the beginning of December 2016.

PolyPeptide Group announced that the harmonization of procedures at the Belgian facility to ensure consistency, continuity and quality within its expanded group will be implemented in the coming months. The integration process is expected to be seamless to customers.

The financial terms of the transaction were not disclosed.